Clinical Trial: Replicor Compassionate Access Program
Condition:
Viral Hepatitis B
Viral Hepatitis D
Cirrhosis, Liver
Decompensated Cirrhosis
Asc
Study Type: Expanded Access
Official Title: Compassionate Use Access to REP 2139-Mg for the Treatment of Chronic HBV Infection or Chronic HBV / HDV Co-infection
Brief Summary:
The goal of this compassionate access program is to provide early access to REP 2139-Mg for patients with HBV mono-infection or HBV / HDV co-infection who either have advanced (decompensated) cirrhosis or who have failed to response to other other antiviral agents either approved or under development and who are in danger of progressing to decompensated cirrhosis.This compassionate access program will provide access to a once weekly regimen of subcutaneously (SC) administered REP 2139-Mg for a period of 48 weeks…
Read more